Published in Am J Clin Nutr on December 30, 2008
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Genome-wide association study of circulating vitamin D levels. Hum Mol Genet (2010) 4.07
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Heritability and seasonal variability of vitamin D concentrations in male twins. Am J Clin Nutr (2010) 1.73
Blood vitamin d levels in relation to genetic estimation of African ancestry. Cancer Epidemiol Biomarkers Prev (2010) 1.22
Blood levels of vitamin D in teens and young adults with myopia. Optom Vis Sci (2011) 1.16
Common variation in vitamin D pathway genes predicts circulating 25-hydroxyvitamin D Levels among African Americans. PLoS One (2011) 1.12
25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. J Clin Endocrinol Metab (2014) 1.10
Genetic variation in the vitamin D receptor (VDR) and the vitamin D-binding protein (GC) and risk for colorectal cancer: results from the Colon Cancer Family Registry. Cancer Epidemiol Biomarkers Prev (2010) 1.07
Exploring the genetic architecture of circulating 25-hydroxyvitamin D. Genet Epidemiol (2012) 1.00
Common variants of the vitamin D binding protein gene and adverse health outcomes. Crit Rev Clin Lab Sci (2013) 0.98
Associations between common variants in GC and DHCR7/NADSYN1 and vitamin D concentration in Chinese Hans. Hum Genet (2011) 0.98
Genetic and environmental predictors of serum 25-hydroxyvitamin D concentrations among middle-aged and elderly Chinese in Singapore. Br J Nutr (2012) 0.97
Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation. Nutr J (2013) 0.93
Vitamin D intake and season modify the effects of the GC and CYP2R1 genes on 25-hydroxyvitamin D concentrations. J Nutr (2012) 0.93
Genome-wide association study of vitamin D concentrations in Hispanic Americans: the IRAS family study. J Steroid Biochem Mol Biol (2010) 0.93
Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev (2011) 0.90
Vitamin D insufficiency in Arabs and South Asians positively associates with polymorphisms in GC and CYP2R1 genes. PLoS One (2014) 0.90
Common variants in CYP2R1 and GC genes predict vitamin D concentrations in healthy Danish children and adults. PLoS One (2014) 0.88
Common vitamin D pathway gene variants reveal contrasting effects on serum vitamin D levels in African Americans and European Americans. Hum Genet (2014) 0.88
Genetic variation in vitamin D-related genes and risk of colorectal cancer in African Americans. Cancer Causes Control (2014) 0.87
Serum 25(OH)D concentrations in sunny Israel. Osteoporos Int (2011) 0.86
Vitamin D and mammographic breast density: a systematic review. Cancer Causes Control (2011) 0.86
GC Glu416Asp and Thr420Lys polymorphisms contribute to gastrointestinal cancer susceptibility in a Chinese population. Int J Clin Exp Med (2012) 0.86
The emerging role of vitamin D binding protein in multiple sclerosis. J Neurol (2010) 0.84
Vitamin d binding protein and bone health. Int J Endocrinol (2014) 0.84
Associations between vitamin D-binding protein isotypes, circulating 25(OH)D levels, and vitamin D metabolite uptake in colon cancer cells. Cancer Prev Res (Phila) (2014) 0.83
Vitamin D binding protein genotype is associated with serum 25-hydroxyvitamin D and PTH concentrations, as well as bone health in children and adolescents in Finland. PLoS One (2014) 0.83
No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case-control study. Arch Dermatol Res (2012) 0.81
The effect of obesity on the relationship between serum parathyroid hormone and 25-hydroxyvitamin D in women. J Clin Endocrinol Metab (2013) 0.80
Vitamin D receptor (VDR) and group-specific component (GC, vitamin D-binding protein) polymorphisms in myopia. Invest Ophthalmol Vis Sci (2011) 0.80
Genetic influences on vitamin D status and forearm fracture risk in African American children. J Investig Med (2012) 0.80
Nutrigenomics and personalized diets: What will they mean for food? Annu Rev Food Sci Technol (2011) 0.79
Influence of the vitamin D plasma level and vitamin D-related genetic polymorphisms on the immune status of patients with type 1 diabetes: a pilot study. Clin Exp Immunol (2013) 0.79
Association of common gene variants in vitamin D modulating genes and colon cancer recurrence. J Cancer Res Clin Oncol (2013) 0.78
Association of single nucleotide polymorphisms in VDR and DBP genes with HBV-related hepatocellular carcinoma risk in a Chinese population. PLoS One (2014) 0.78
Genetic and environmental factors are associated with serum 25-hydroxyvitamin D concentrations in older African Americans. J Nutr (2015) 0.78
Relationship between polymorphisms in vitamin D metabolism-related genes and the risk of rickets in Han Chinese children. BMC Med Genet (2013) 0.77
Selected vitamin D metabolic gene variants and risk for autism spectrum disorder in the CHARGE Study. Early Hum Dev (2015) 0.76
Polymorphisms in GC and NADSYN1 Genes are associated with vitamin D status and metabolic profile in Non-diabetic adults. BMC Endocr Disord (2013) 0.76
Genetic Polymorphisms in Vitamin D Metabolism and Signaling Genes and Risk of Breast Cancer: A Nested Case-Control Study. PLoS One (2015) 0.75
Real-life use of vitamin D3-fortified bread and milk during a winter season: the effects of CYP2R1 and GC genes on 25-hydroxyvitamin D concentrations in Danish families, the VitmaD study. Genes Nutr (2014) 0.75
Genetic variant in vitamin D-binding protein is associated with metabolic syndrome and lower 25-hydroxyvitamin D levels in polycystic ovary syndrome: A cross-sectional study. PLoS One (2017) 0.75
Association between intake of sugar-sweetened beverages and circulating 25-hydroxyvitamin D concentration among premenopausal women. Nutrients (2014) 0.75
Concerning the vitamin D reference range: pre-analytical and analytical variability of vitamin D measurement. Biochem Med (Zagreb) (2017) 0.75
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
Diabetes and cancer: a consensus report. CA Cancer J Clin (2010) 3.95
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.25
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst (2002) 3.03
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 2.70
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
Can pain be managed through the Internet? A systematic review of randomized controlled trials. Pain (2011) 2.66
Work situation after breast cancer: results from a population-based study. J Natl Cancer Inst (2004) 2.57
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res (2008) 2.37
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol (2004) 2.32
Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev (2005) 2.28
Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev (2003) 2.26
A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst (2004) 2.22
Influence of delay to diagnosis on prognostic indicators of screen-detected breast carcinoma. Cancer (2002) 2.03
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer (2008) 1.96
mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab (2013) 1.91
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene (2005) 1.89
Wage losses in the year after breast cancer: extent and determinants among Canadian women. J Natl Cancer Inst (2008) 1.80
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76
Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol (2011) 1.66
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol (2008) 1.64
Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) (2010) 1.62
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer (2010) 1.61
Insulin receptor expression by human prostate cancers. Prostate (2009) 1.57
Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst (2007) 1.53
Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis (2012) 1.52
Mortality among Canadian women with cosmetic breast implants. Am J Epidemiol (2006) 1.51
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One (2008) 1.50
Radiologist interpretive volume and breast cancer screening accuracy in a Canadian organized screening program. J Natl Cancer Inst (2014) 1.49
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res (2002) 1.48
Work absence after breast cancer diagnosis: a population-based study. CMAJ (2005) 1.43
Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A (2012) 1.43
Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer (2004) 1.42
Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev (2010) 1.39
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res (2009) 1.37
Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers. Cancer Causes Control (2014) 1.37
Investigating the correlation between hospital of primary treatment and the survival of women with breast cancer. Cancer (2005) 1.33
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med (2011) 1.31
Dietary change after breast cancer: extent, predictors, and relation with psychological distress. J Clin Oncol (2002) 1.31
Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res (2003) 1.31
Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res (2011) 1.28
Not working 3 years after breast cancer: predictors in a population-based study. J Clin Oncol (2005) 1.28
Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol (2011) 1.27
Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomarkers Prev (2005) 1.27
The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res (2006) 1.25
Wolfe's parenchymal pattern and percentage of the breast with mammographic densities: redundant or complementary classifications? Cancer Epidemiol Biomarkers Prev (2003) 1.25
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res (2008) 1.25
Vitamin D, calcium, and mammographic breast densities. Cancer Epidemiol Biomarkers Prev (2004) 1.24
Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin d. Cancer Epidemiol Biomarkers Prev (2007) 1.24
Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev (2002) 1.23
Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res (2006) 1.23
Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res (2007) 1.23
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res (2005) 1.22
Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest (2003) 1.18
A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate (2010) 1.18
Plasma concentrations of polychlorinated biphenyls and the risk of breast cancer: a congener-specific analysis. Am J Epidemiol (2002) 1.18
Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit (2002) 1.18
Herbaceous covers to control tree invasion in rights-of-way: ecological concepts and applications. Environ Manage (2004) 1.17
C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol (2007) 1.17
Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet (2010) 1.16
Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol (2008) 1.15
Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem Biophys Res Commun (2011) 1.14
The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila) (2009) 1.13
Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol (2006) 1.12
mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle (2015) 1.11
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res (2011) 1.11
IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal (2012) 1.09
Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat (2011) 1.08
Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol (1985) (2012) 1.08
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res (2005) 1.08
Influence of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. Cancer Res (2006) 1.08
Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes (2012) 1.08
Luminal administration ex vivo of a live Lactobacillus species moderates mouse jejunal motility within minutes. FASEB J (2010) 1.08
Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr (2012) 1.07
A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer. Breast Cancer Res Treat (2004) 1.06
Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. Am J Epidemiol (2002) 1.06
Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev (2008) 1.05
Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets (2009) 1.04
Out-of-pocket costs for accessing adjuvant radiotherapy among Canadian women with breast cancer. J Clin Oncol (2011) 1.03
Volume of screening mammography and performance in the Quebec population-based Breast Cancer Screening Program. CMAJ (2005) 1.03
Effect of exercise on cancer-related fatigue: a meta-analysis. Am J Phys Med Rehabil (2014) 1.02
Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs (2009) 1.02
Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.02